FDA’s Postmarketing Powers Force Shionogi To Withdraw Rybix ODT
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency says Shionogi’s orally disintegrating tramadol is misbranded because the firm did not submit a post-marketing trial protocol in time, but the company states the trial is not worth the expense and will withdraw the product.
You may also be interested in...
Postmarketing Safety Studies: US FDA Defines ‘Good Cause’ For Missing Milestone Dates
A company is in violation for missed PMR milestones unless good cause has been demonstrated for noncompliance. New draft guidance, issued 16 years after the FDA gained the authority to require postmarketing safety studies, provides examples of when good cause exists and encourages sponsors to notify the agency in advance of missed deadlines.
Merck’s Postmarketing Study Delays Prompt FDA To Unsheathe New Enforcement Power
Januvia and Janumet are misbranded, FDA tells Merck in a warning letter noting that rodent safety studies for the sitagliptin diabetes drugs were 20 months behind schedule. The letter marks the first time FDA has used its FDAAA powers to take enforcement action against a pharma company for such a delay.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.